• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of child and adolescent psychopharmacology

    Journal of child and adolescent psychopharmacology

    JournalISSN 1044-5463eISSN 1557-8992中科院 医学 4区

    年发文量

    研究主题

    论文(3033)

    排序
    1Efficacy of Centanafadine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and High Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials.
    Timothy E. Wilens,Ann C. Childress,Greg W. Mattingly,Judy van Stralen, Gregory S. Parks,Zhen Zhang,Taisa Skubiak,Caroline L. Ward

    Objectives: High levels of executive dysfunction associated with attention-deficit/hyperactivity disorder (ADHD) have been linked to poorer response to pharmacotherapy. This post hoc analysis assessed the efficacy of centanafadine in the treatment of ADHD core symptoms and associated features in a subgroup of children and adolescents with high executive dysfunction. Methods: Data were pooled from two phase 3, multicenter, randomized, double-blind, placebo-controlled trials conducted in the United States and Canada in children (6–12 years) and adolescents (13–17 years) with a primary diagnosis of ADHD who received centanafadine or placebo for 6 weeks. High levels of executive dysfunction were defined using a baseline Conners 3–Parent Short Executive Function T-score of ≥70. Efficacy outcomes assessed change from baseline in ADHD core symptoms and associated features. The p values were not controlled for multiplicity. Effect sizes were calculated using Cohen’s d method based on mixed models for repeated measures estimates and are shown for outcomes that separated from placebo. Results: Among 435 participants with high executive dysfunction, baseline ADHD Rating Scale-5 (ADHD-RS-5) total scores and Conners 3–Parent Short T-scores for Inattention, Hyperactivity/Impulsivity, Defiance/Aggression, and Learning Problems were all greater than in the low dysfunction subgroup. By Week 6, ADHD-RS-5 scores in the centanafadine-treated high dysfunction subgroup were similar to those in the centanafadine-treated low dysfunction subgroup and were lower than in the placebo-treated subgroups. Over Weeks 1–6, effect sizes in the high executive dysfunction subgroup ranged from 0.35 to 0.51 for ADHD-RS-5, 0.33 to 0.56 for Conners 3–Parent Short Inattention, 0.33 to 0.43 for Hyperactivity/Impulsivity, 0.34 to 0.53 for Executive Function, 0.36 to 0.52 for Learning Problems, and 0.19 to 0.36 for Defiance/Aggression. No new safety concerns were identified. Conclusions: Individuals aged 6–17 years with high levels of executive dysfunction achieved greater improvements in ADHD core symptoms and in several associated features, including executive dysfunction and emotional dysregulation, following centanafadine treatment when compared with placebo.

    2026
    引用
    AI阅读
    加入学术空间
    2Letter: Visual Hallucinations Beyond Psychosis: Peduncular Hallucinosis and Charles Bonnet Syndrome in Pediatric and Young Adult Patients
    Muhammad Zain, Saad Nadeem, Sana Younus, Kimberly C. Davis, Chadi Calarge
    2026
    引用
    AI阅读
    加入学术空间
    3Subcutaneous Esketamine in Adolescents with Severe Depressive Episodes: A Five-Case Series
    Iury P. A. Magalhaes, Daniel N. Lopes, Isabel A. Amato,Marcos V. V. Ribeiro, Rodrigo A. Luz,Rodrigo S. Delfino, Juliana C. Surjan,Acioly L. T. Lacerda,Sheila C. Caetano

    Objective: To describe the feasibility, acute tolerability, and short-term symptom trajectories of adjunctive subcutaneous esketamine in adolescents with severe depressive episodes treated in specialized outpatient care.Methods: This observational case series included five adolescents aged 15-17 years with severe depressive symptoms, suicidal ideation and/or behavior, and insufficient response to previous treatments. Patients received eight once-weekly subcutaneous esketamine sessions, starting at 0.5 mg/kg and titrated up to 1.0 mg/kg based on clinical response and tolerability. Depressive symptoms were assessed using the Montgomery-& Aring;sberg Depression Rating Scale (MADRS). MADRS-rated suicidal ideation and anhedonia-related symptoms were examined descriptively using MADRS Items 10 and 8, respectively; Item 8 was considered an indirect indicator of anhedonia-related symptoms.Results: All patients completed the eight-session treatment course. Overall, MADRS trajectories were heterogeneous: one patient achieved remission, three presented varying degrees of partial improvement, and one showed no sustained benefit. MADRS Item 10 scores decreased from baseline to endpoint in four patients, and MADRS Item 8 scores decreased in four patients. Acute adverse effects included transient dissociative symptoms with mild agitation in one patient and mild transient elevations in blood pressure in some cases. No severe acute adverse events, emergency interventions, psychiatric hospitalizations, suicide attempts, or clear manic switches were documented during the 8-week protocol.Conclusions: In this small uncontrolled case series, adjunctive subcutaneous esketamine was feasible under close monitoring and was associated with heterogeneous short-term depressive symptom trajectories. Decreases in MADRS-rated suicidal ideation and MADRS Item 8 scores should be considered hypothesis-generating and do not establish antidepressant efficacy, domain-specific effects, or reduced suicide risk. Controlled pediatric studies with standardized dosing, suicide-specific assessments, systematic safety monitoring, and longer follow-up are needed.

    2026
    引用
    AI阅读
    加入学术空间
    4Letter: Lisdexamfetamine for Improving Symptoms of Cognitive Disengagement Syndrome after Trials of Methylphenidate in an 11-Year-old Girl with FOXP1 Syndrome
    Samuel Testut, Alice Oppetit,David Cohen,Xavier Benarous
    2026
    引用
    AI阅读
    加入学术空间
    5The Art of Prescribing, Toward a Goldilocks Model of Psychotropic Prescribing in Youth
    Fiona McNicholas, Laura Bond,Diane Purper-Ouakil,John T. Walkup,John C. Hayden, Rebecca Parkin
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3033 篇论文

    高被引作者

    作者引用发文
    Roland Shytle150374
    David V. Sheehan148912
    Juris Janavs148901
    Bannon Yvonne148901
    Karen M. Milo148901
    Stock Saundra L148901
    Kathy H. Sheehan148901
    Jamison Rogers148901
    Melissa P. Delbello361968
    Joseph Biederman307147

    高产作者

    作者引用发文
    Barbara Coffey811142
    Melissa P. Delbello361968
    Robert L. Findling226759
    Jeffrey R. Strawn73253
    Michael G. Aman236449
    Eugene Arnold184248
    Joseph Biederman307147
    Paul E. Croarkin41044
    Harold S. Koplewicz4441
    Chris McDougle198341

    相关期刊

    Journal of clinical psychopharmacology
    Harvard review of psychiatry
    Nordic journal of psychiatry
    Psychiatric annals
    CNS spectrums
    The primary care companion for CNS disorders
    Case reports in psychiatry
    International Journal of Bipolar Disorders
    Annals of Clinical Psychiatry
    Psychiatric Clinics of North America